Zenas BioPharma Secures $2B+ Deal for MS Drug from InnoCare
Zenas BioPharma acquires global rights to orelabrutinib, an experimental multiple sclerosis drug from InnoCare Pharma, in a licensing deal worth over $2 billion with $120M funding secured.
/ 1 item
#ZBIO↓